Good afternoon, everyone, and welcome to Alphatec's Third Quarter 2018 Conference Call. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on current expectations and are subject to uncertainties that could cause actual results to differ materially. These uncertainties are detailed in documents filed regularly with the SEC. During this call, you may hear the company refer to reported amounts, which are in accordance with U.S. GAAP as well as non-GAAP or pro forma measures. Reconciliation of non-GAAP measures to U.S. GAAP can be found in the supplemental financial tables included in the press release, which identify and quantify all excluded items and provide management's views of why this information is useful to investors. Joining us on the call today will be ATEC's Chairman and CEO, Pat Miles; President and COO, Terry Rich; and CFO, Jeff Black. Now I'll turn the call over to Pat Miles.

Thanks, Rishi, and welcome, everyone. We're pleased to report our results for the third quarter, which demonstrate continued transformation. Total U.S. commercial revenue was $21 million, up 3% compared to the second quarter of 2018. The sequential growth is a testament to the strength of our results given the historical third quarter seasonal weakness in spine. We continue to see solid progress on our path to accelerated growth, as evidenced by several major accomplishments. Our U.S. commercial business achieved year-over-year revenue growth for the first time since we began the process of reducing nonstrategic distributor relationships in 2017. Secondly, our team started making its mark on ATEC portfolio with the new product Alpha releases. Additionally, we obtained financial independence from an industry competitor with a new term loan that will free up $27 million over the next 3 years. Terry will go into the demographics of revenue growth, and Jeff will provide detail on the debt refinancing in a moment. Turning to guidance. We now have greater clarity into how the remainder of the year will progress and are updating our 2018 revenue guidance to a range of $92 million to $95 million compared to our previous guidance of approximately $95 million. This guidance reflects anticipated fourth quarter domestic growth of greater than 10% on both the sequential and year-over-year basis. Over the past decade, the industry's leading innovators have been the pure-play spine companies. Their focused commitment has been rewarded with revenue growth that has exceeded the broader market. The team that drove much of the innovation now resides at Alphatec. We continue to add profound spine experience with the employment of Mark Ojeda, to lead our cervical and biologics effort. Mark has a proven track record integrating multiple technologies into highly differentiated procedural solutions and has particularly deep…

Thank you, Pat, and good afternoon everyone. As Pat mentioned, our U.S. commercial business achieved year-over-year revenue growth for the first time since we began the process of reducing nonstrategic distributor relationships in early 2017. It's exciting to see the revenue growth from our expanding dedicated sales channel and surgeon adoption begin to outpace revenue losses associated with that transition. Now I'll turn to our second strategic priority, revitalizing our sales channel. We continue to partner with more clinically focused, higher-volume, dedicated distributors and direct sales teams. In the third quarter, we expanded the percentage of U.S. commercial revenue driven by dedicated distribution partners to 63%, up from 40% at the end of 2017. Year-to-date, the revenue driven by the dedicated portion of our network has almost tripled compared to the first 3 quarters of last year. We also continue to solidify our sales leadership team by leveraging both the excitement about ATEC in the field and the ongoing desire of sales talent to move to companies focused on winning market share through innovation. The third quarter additions of Emory Rooney, Darrell Wilson and Mason Zabel bring decades of spine experience to the team. Each of them has a proven track record of driving surgeon adoption and building high-performance teams without the benefit of a highly differentiated portfolio. I look forward to seeing what they will accomplish when backed by innovation. Our third strategic priority is driving surgeon adoption of the ATEC portfolio, a complex endeavor considering the legacy portfolio's limited differentiation. The surgeons who are partnering with us today recognize and believe wholeheartedly and our team's ability to deliver meaningful clinical distinction. As a result of that conviction and the surgeon interest that our enhanced sales channel is driving, a record number of surgeons visited ATEC headquarters to participate in our educational programs during the third quarter. Importantly, conversion of these new relationships is both strong and accelerating. Third quarter revenue attributable to new surgeon customers continued to substantially outpace overall revenue growth. Also, the ramp of new surgeon relationships has accelerated in each quarter this year. We are demonstrating clear progress against the initiatives that we believe will reposition this organization and accelerate growth. I'll now turn the call over to Jeff.

Thank you, Terry, and good afternoon, everybody. Third quarter U.S. commercial revenue was $21 million, up 3% sequentially. And our dedicated distribution channel achieved sequential revenue growth of about 14%, significantly outpacing overall revenue growth. U.S. gross margin was 70.1% in the third quarter compared to 69.5% in the second quarter, in line with our expectations. Our non-GAAP operating expenses, which exclude restructuring, stock-based compensation, transaction-related expenses and fair value adjustments, were $20 million in the third quarter compared to $19.4 million the second quarter. And we continue to drive expense rationalization across all business functions, particularly in G&A. Excluding stock-based compensation and litigation-related costs, our G&A has been relatively flat over the past 3 quarters. But at the same time, we're investing in areas of the business that we expect to drive accelerated commercial growth, particularly product development and sales and marketing. And as a result, our operating expenses have increased relative to 2017. We ended the third quarter with just over $35 million in cash. Our cash burn in the quarter included $1 million in final cash purchase price adjustments or -- I'm sorry, purchase price payments to SafeOp shareholders for our March acquisition and $833,000 for our first principal payment on our 2016 term loan, which we've now retired in full. Excluding total debt service and our SafeOp shareholder payments, operating cash usage in the quarter was $6.4 million. With the proceeds from the $35 million and financing from Squadron Capital that we announced today, we retired our $29.2 million term loan. This new financing not only frees us from financial dependence on a competitor, but it also reduces our cost of debt capital by roughly 5% and pushes out amortization by an additional 30 months. Our debt service cash requirements will be reduced by almost $27 million over the next 3 years, significantly enhancing our flexibility during a critical time for growth-related investments. We are pleased to be partnering with Squadron, a long-term strategic investment. We'll now turn the call over to Pat for closing comments.

Thanks, Jeff. I recently celebrated my first year anniversary at ATEC. As I look back over the past year, I'm exceedingly proud of the progress we have made with this transformation. When I started, I said the spine market needs a new ATEC. And over the course of the year, the groundwork that we have laid to create value in spine has increased my conviction in the market opportunity in front of us. In just 1 year, the collective know-how of this team has already begun to create clinical distinction. We acquired the SafeOp technology to enable unprecedented automated information and to drive real-time interoperative decision-making across all ATEC procedures. We have successfully worked with the FDA to expediently clear multiple products and are on track to launch 12 new Alpha solutions in 2018. We made great strides in transforming the sales channel, doubling the percentage of the channel that is dedicated and nearly tripping the revenue generated by that group. Those efforts have improved surgeon adoption, driving a meaningful increase in revenue derived from the new surgeon relationships over the course of the past year. As a result, revenue has begun to grow sequentially. Certainly, there's still a lot of work to do. But when I look at what we've accomplished in a year, it is no secret why there is absolutely palpable undercurrent of enthusiasm for ATEC within the spine market. Spine's greatest expertise has begun to create an organic innovation machine, a machine capable of launching 8 to 10 new solutions each year and repositioning this organization at the very forefront of clinical distinction. The track record of this team confirms that a relentless focus on improving spine surgery will drive sustainable growth. The stage is set. We are just beginning to pioneer profound innovation in a market that is absolutely ripe for it. I'll now turn the call back over to the operator, and we will take your questions.

[Operator Instructions] Our first question comes from the line of Brooks O'Neil from Lake Street Capital. Your line is open.

Congratulations on all you've accomplished so far. I'm excited about the future. So my first question, I was hoping that you might discuss just a little bit how your Alpha Informatics from your SafeOp acquisition is going to change within the OR, the operation of spine surgeons, while they use your equipment?

Yes, Brooks. Thanks very much. It's, I think what we see is that surgeons are yearning for information, and they're yearning for information that's available immediately when they need it. And so one of the great things about the Alpha Informatics platform, and the first feature set will be in neurophysiology, will be that we are able to tell surgeons, hey, if you're using a minimally invasive approach, you are heading toward a nerve root. We'll be able to tell a surgeon that in real time so that they can redirect their course and also keep incision small enough to where they don't have to visually see it. Additionally, we'll be able to tell surgeons, hey, you're retracting this nerve and there will be objective information that would suggest that there's been changes in the recordings of some of the monitoring to suggest that he's been retracting too long or too much. And so that type of information is what surgeons want so what they can do is make changes in real time in the operating room. And there's very few techniques in spine where nerve is not retracted. So the applicability really goes across many procedures.

That's very helpful. So I just want to clarify, I have a sense that in today's world, there's a technician sitting in an OR doing the neuromonitoring and in some way, communicating with a physician at a remote location, whereas with your system, it'll be real time, direct information to the doctor during the procedure. Is that right?

Yes, that's right. But I think the beauty of the technology is that it really avails itself to, if a surgeon has a neurophysiology partner that he feels strongly, has a strong relationship with and a great deal of trust in, this piece of equipment can be used with a neurophysiologist or without a neurophysiologist. We want to make sure that the technology is available for all situations.

That makes sense. That's very helpful. So if you could just help us understand where you are with the 12 Alpha launches as well as. Are there, are they all marketplace today? Are there some more coming in Q4? Just give us as a sense for where you're at on that.

Thanks. I'll tell you. Like we are running at them. So one of the fun things is we have a next-generation thoracolumbar fixation system literally going out next week. And these are huge systems where there is thousands of parts involved in these Alpha launches. And so we'll have an MIS, an open fixation system go out next week. We have a number of the porous titanium implants in market now. OsseoScrew will release in Alpha form here in the next month. And we'll have a few more implants released before year-end. So I would tell you that we are sprinting at the end of the year, and this is what this group does best. And so I can't be more enthusiastic with regard to what we've assembled to date and clearly what's forthcoming.

[Operator Instructions] Next question comes from the line of Scott Gambill from Gardner Financial. Your line is open.

Hello everybody. Do guys happen to hear a little bit of an echo out there?

We don't.

No? Okay. It's just my end then. All right. I'll get through it. I just had a question on the guidance for the year. It looks like you kind of pulled the low end, you gave us a range now, and it's a little, $92 million, $95 million. Was part of that because of maybe some timing of these new product launches?

Yes, Scott, this is Pat. I would say that it's a little lumpiness in terms of, we are making so many additions to the sales force. And the timing of when these guys get out has been a bit, a little bit lumpy and we've been, the clarity in terms of exactly where they'd contribute. The other things are we're running at these Alphas and trying to get hospital approvals and things of that nature. So if there's a little bit of a drag in some of the top line based upon just the hospital approval, we just want to make sure that we're being thoughtful.

Yes, okay. Makes total sense. I just wanted to see if I could get a little bit certain about my thoughts on that. The only other question I have right now is looking at the loss, operating losses. I know they've climbed this year, and I know it's because of the build that you guys are doing internally. But I'm just wondering if you could maybe share your vision of how the company gradually works towards profitability and maybe when you might have a target for that.

Yes, Scott, this is Jeff. We're not, we, at this point, are not going to provide any forward guidance on profitability. But I think the way to think about the business is that, for sure, we'll continue to invest in R&D with the intent of releasing 8 to 10 new products. But we will start to see scale in operating leverage once we start to scale the business. So we'll see sales expenses come down as a percentage over time. We'll certainly see scale in the G&A line. You'll see that we've actually taken a pretty hard line and tried to keep core G&A relatively flat. So I think the way to think about it is that continued investment in R&D with operating leverage as we scale the revenue line.

Okay. Would that scaling be something that I should anticipate next year?

Yes, I think you'll start seeing it. But I think ultimately, it's really next year about making sure that we have the right investment in sales and marketing and product development and get this 12 new Alphas into commercial launch. So I think that when you really start seeing the benefit of scale is probably later in 2019 and 2020.

Okay that's great. Thanks a lot Jeff.

You bet. Thank you.

[Operator Instructions] I am showing no further questions at this time. I would now like to turn the conference back to Pat Miles.

Thanks much, Rishi. Appreciate everybody who has participated on the call, and we look forward to being in touch next quarter. Thanks much. Take care.

Ladies and gentlemen, this concludes today's conference. Thank you for your participation, and have a wonderful day. You may now all disconnect.